Antibody-drug conjugate (HER2)
Kadcyla (ado-trastuzumab emtansine) cost
Manufacturer: Genentech · Route: injection/infusion (Part B) · HCPCS: J9354 · Last updated
Medicare spending — 2023
$63,229
Average total Medicare spending per beneficiary per year
$9,667
Average spending per claim
$37.29
Average Sales Price per mg
Source: CMS Medicare Part B Spending by Drug, data year 2023.
What patients actually pay
The $63,229 figure above is total Medicare spending — the government's payment — not what a patient pays out of pocket. Actual out-of-pocket varies widely:
- Original Medicare + Medigap supplemental policy: typically covers most of the 20% Part B coinsurance, leaving minimal out-of-pocket.
- Medicare Advantage: caps annual out-of-pocket spending ($8,850 in 2024 for in-network care, lower for some plans).
- Commercial insurance: copay or coinsurance varies; specialty drugs often require prior authorization. See "financial assistance" below.
- Uninsured: manufacturer patient assistance programs can provide Kadcyla at no cost for income-eligible patients. See below.
The ASP of $37.29 per milligram is the federal Medicare reimbursement rate. Dose depends on your weight and indication — most Kadcyla regimens are hundreds to thousands of mg per cycle.
Cancers this drug treats
FDA-approved indications for Kadcyla on our site. For each, see the complete treatment landscape plus active clinical trials.
Financial assistance for Kadcyla
The manufacturer of Kadcyla offers a patient assistance program. Disease-specific foundations also fund copay assistance for the cancers this drug treats.
Genentech Access Solutions
Manufacturer programbenefit investigation · copay assistance referral
https://www.genentech-access.com/patient.html · 877-436-3683
Disease foundations with funds covering Kadcyla's cancers
HealthWell Foundation
copay, premium, and deductible assistance for insured patients; fund availability varies by disease
https://www.healthwellfoundation.org/disease-funds/
Funds open and close based on availability; check disease-funds page for current status
Patient Access Network (PAN) Foundation
copay assistance for 20+ cancer types via disease-specific funds
https://www.panfoundation.org/find-disease-fund/ · 866-316-7263
Merging with Patient Advocate Foundation; unified 'TotalAssist' program launches 2026-07-01
Patient Advocate Foundation Co-Pay Relief
direct copay / coinsurance assistance via disease-specific funds
https://copays.org/ · 866-512-3861
Merging with PAN Foundation; launching 'TotalAssist' 2026-07-01
CancerCare Co-Payment Assistance Foundation
copay assistance for chemotherapy and targeted treatment medications
https://www.cancercare.org/copayfoundation · 866-552-6729
CancerCare Financial Assistance
limited financial assistance for transportation, home care, child care, and treatment-related costs
https://www.cancercare.org/financial · 800-813-4673
Susan G. Komen Financial Assistance
patient navigation + financial assistance for breast cancer patients
https://www.komen.org/support-resources/financial-assistance/
Also try these directory aggregators: NeedyMeds, RxAssist, Cancer Financial Assistance Coalition (CFAC).
Clinical trials using Kadcyla
Trials testing ado-trastuzumab emtansine in new combinations, new cancer types, or earlier lines of therapy. Trials often cover the cost of the drug.
Or search ClinicalTrials.gov directly for ado-trastuzumab emtansine.